Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Open Access
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 76 (8), 1075-1082
- https://doi.org/10.1007/s00228-020-02888-y
Abstract
Purpose The aim of this study was to ascertain whether the absolute bioavailability of oral imatinib (Glivec (R)) during steady state plasma pharmacokinetics in cancer patients could be determined through a concomitant intravenous administration of a single 100 mu g microdose of deuterium labeled imatinib (imatinib-d8). Secondly, the usefulness of liquid chromatography-tandem mass spectrometry (LC-MS/MS) was investigated for simultaneous analysis of orally and intravenously administered imatinib. Methods Included patients were on a stable daily dose of 400 mg oral imatinib prior to study participation. On day 1, patients received a 100 mu g intravenous imatinib-d8 microdose 2.5 h after intake of the oral dose. Plasma samples were collected for 48 h. Imatinib and imatinib-d8 concentrations were simultaneously quantified using a validated LC-MS/MS assay. The absolute bioavailability was calculated by comparing the dose-normalized exposure with unlabeled and stable isotopically labeled imatinib in plasma. Results A total of six patients were enrolled. All patients had a history of gastrointestinal stromal tumors (GIST). The median absolute bioavailability of oral imatinib at steady state was 76% (range 44-106%). Imatinib and imatinib-d8 plasma concentrations were quantified in all collected plasma samples, with no samples below the limit of quantification for imatinib-d8. Conclusion The absolute bioavailability of imatinib was successfully estimated at steady state plasma pharmacokinetics using the stable isotopically labeled microdose trial design. This study exhibits the use of a stable isotopically labeled intravenous microdose to determine the absolute bioavailability of an oral anticancer agent in patients with LC-MS/MS as the analytical tool.Funding Information
- Utrecht University
This publication has 18 references indexed in Scilit:
- Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracersThe Journal of Clinical Pharmacology, 2015
- Variability in bioavailability of small molecular tyrosine kinase inhibitorsCancer Treatment Reviews, 2015
- A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST PatientsClinical Cancer Research, 2012
- Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposureInvestigational New Drugs, 2011
- Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to ImatinibJournal of Clinical Oncology, 2010
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2009
- The use of isotopes in the determination of absolute bioavailability of drugs in humansExpert Opinion on Drug Metabolism & Toxicology, 2006
- METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERSDrug Metabolism and Disposition, 2005
- Clinical Pharmacokinetics of ImatinibClinical Pharmacokinetics, 2005
- Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupCancer Chemotherapy and Pharmacology, 2004